Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Sodium-glucose cotransporter 2(SGLT2) inhibitors show prominent renal protective effect in diabetic kidney disease (DKD), anti-inflammatory effect being one of its key mechanisms. Over-activation of the complement system, a crucial part of innate immunity, plays an important role in DKD. We aimed to...

Full description

Bibliographic Details
Main Authors:	Dong-Yuan Chang, Xiao-Qian Li, Min Chen, Ming-Hui Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Series:	Frontiers in Pharmacology
Subjects:	sodium glucose co-transport-2 (SGLT2) inhibitors dapagliflozin diabetic kidney disease complement over-activation complement receptor type 1-related protein y (Crry) hypoxia inducible factor-1α (HIF-1 α)
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.729334/full

Similar Items

C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice
by: Nirmal K. Banda, et al.
Published: (2020-10-01)

Induced neural stem cell grafts exert neuroprotection through an interaction between Crry and Akt in a mouse model of closed head injury
by: Mou Gao, et al.
Published: (2021-02-01)

Complement Component 5 (C5) Deficiency Improves Cognitive Outcome After Traumatic Brain Injury and Enhances Treatment Effects of Complement Inhibitors C1-Inh and CR2-Crry in a Mouse Model
by: Min Chen, et al.
Published: (2023-10-01)

Complement Inhibition Alleviates Cholestatic Liver Injury Through Mediating Macrophage Infiltration and Function in Mice
by: Zhenya Guo, et al.
Published: (2022-01-01)

Precise dapagliflozin delivery by cardiac homing peptide functionalized mesoporous silica nanocarries for heart failure repair after myocardial infarction
by: Lijiao You, et al.
Published: (2022-11-01)

Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway
by: Jingyao Yang, et al.
Published: (2023-09-01)

Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report
by: Yan Tian, et al.
Published: (2023-04-01)

PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice
by: Xiaomeng Feng, et al.
Published: (2021-06-01)

HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR)
by: Chang W. Song, et al.
Published: (2022-07-01)

Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis
by: Soltys Jindrich, et al.
Published: (2012-05-01)

Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation
by: Ying Zhou, et al.
Published: (2023-09-01)

Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives
by: Nashar K, et al.
Published: (2022-11-01)

Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes
by: Shi Tai, et al.
Published: (2023-08-01)

Dapagliflozin Aggravates Renal Injury via Promoting Gluconeogenesis in db/db Mice
by: Yingli Jia, et al.
Published: (2018-02-01)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
by: Zhi Zeng, et al.
Published: (2021-07-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Hypoxia-Inducible Factor 1 and Mitochondria: An Intimate Connection
by: Xiaochen Huang, et al.
Published: (2022-12-01)

High expression of NDRG3 in osteoarthritis patients
by: Long Chen, et al.
Published: (2021-03-01)

Investigating the Cardiovascular Benefits of Dapagliflozin: Vasodilatory Effect on Isolated Rat Coronary Arteries
by: Sooyeon Choi, et al.
Published: (2023-11-01)

The effects of dapagliflozin on serum electrolytes concentration in adult male rats
by: Muhsin S. G. Al-Mozie'l, et al.
Published: (2018-12-01)

Hemopexin Modulates Expression of Complement Regulatory Proteins in Rat Glomeruli
by: Maria G. Detsika, et al.
Published: (2021-09-01)

Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan
by: Jung-Fu Chen, et al.
Published: (2020-11-01)

JAK1 inactivation promotes proliferation and migration of endometrial cancer cells via upregulating the hypoxia-inducible factor signaling pathway
by: Qin Lin, et al.
Published: (2022-11-01)

Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure
by: Xuefeng Chen, et al.
Published: (2022-05-01)

Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2022-12-01)

Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide
by: Charlotte C. van Ruiten, et al.
Published: (2022-05-01)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01)

The transition from HIF-1 to HIF-2 during prolonged hypoxia results from reactivation of PHDs and HIF1A mRNA instability
by: Maciej Jaśkiewicz, et al.
Published: (2022-12-01)

Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice
by: Jin Joo Cha, et al.
Published: (2024-01-01)

A Novel Cargo Delivery System‐AnCar‐ExoLaIMTS Ameliorates Arthritis via Specifically Targeting Pro‐Inflammatory Macrophages
by: Song Li, et al.
Published: (2024-02-01)

CHD1 deletion stabilizes HIF1α to promote angiogenesis and glycolysis in prostate cancer
by: Yu-Zhao Wang, et al.
Published: (2023-01-01)

Effect of Dapagliflozin in Patients with Heart Failure: A Systematic Review and Meta-Analysis
by: Ahmed E. Ali, et al.
Published: (2023-08-01)

Peritumor Mucosa in Advanced Laryngeal Carcinoma Exhibits an Aberrant Proangiogenic Signature Distinctive from the Expression Pattern in Adjacent Tumor Tissue
by: Silva G. Kyurkchiyan, et al.
Published: (2024-04-01)

Impact of dapagliflozin on life expectancy in type 2 diabetes mellitus patients in routine practice
by: M. B. Antsiferov, et al.
Published: (2023-08-01)

Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function
by: Zakaria Hamdan, et al.
Published: (2024-01-01)

Obtención de un preparado del componente C1 (q,r,s) del sistema complemento Obtaining a preparation of C1 component (q,r,s) of the complement system
by: Julio C Merlín Linares, et al.
Published: (2002-12-01)

Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases
by: Katherine eLintner, et al.
Published: (2016-02-01)

Clinical studies of dapagliflozin in pediatric patients: a rapid review
by: Paige M. Grube, et al.
Published: (2022-12-01)

Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
by: Sabrina Kuoni, et al.
Published: (2024-02-01)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
by: Charlotte C. van Ruiten, et al.
Published: (2022-04-01)